Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070236 · ClinicalTrials.gov registry record · NA
PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions
A NA study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 912
- Enrollment target
- 6
- Study locations
NCT03070236 is a NA study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 912 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (67% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT03070236, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 912 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is evaluating how patients feel physically and emotionally after a prior breast biopsy for specific breast conditions (including atypical lesions such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and/or ductal carcinoma in situ (DCIS))
Conditions Studied
Interventions
- OTHER Survey
Study Locations (6)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Newton-Wellesley Hospital - Newton
- Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital - Weymouth
North Carolina
- Duke University Medical Center - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 912 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2030-02-25 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070236
The ClinicalTrials.gov registry entry for NCT03070236 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 912 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (67% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Survey is the first listed.
NCT03070236 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT03070236 about?
NCT03070236 is a clinical study titled "PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions". This research study is evaluating how patients feel physically and emotionally after a prior breast biopsy for specific breast conditions (including atypical lesions such as atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and/or ductal carcino...
What is the current status of trial NCT03070236?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 912 participants. The study started on 2017-12-01. Estimated completion is 2030-02-25.
What conditions does trial NCT03070236 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03070236?
The interventions under investigation include: Survey (OTHER).
Who is sponsoring clinical trial NCT03070236?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03070236 being conducted?
This trial has 6 study locations across Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.